In this paper, we will comprehensively review the expression and function of TIM-3 in MDS, explore its immunoregulatory mechanism in the process of disease onset, development and transformation, and describe the current application value of TIM-3 in MDS treatment. This evidence concerns the gene HAVCR2 and myelodysplastic syndrome.